LYEL Key Statistics, Chart & Performance
The current stock price of LYEL is 38.6 USD. In the past month the price increased by 71.33%. In the past year, price increased by 196.92%.
LYEL Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.33 | 406.30B | ||
| AMGN | AMGEN INC | 15.27 | 179.83B | ||
| GILD | GILEAD SCIENCES INC | 15.34 | 155.92B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.67 | 117.47B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.41 | 82.37B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 785.67 | 52.94B | ||
| INSM | INSMED INC | N/A | 37.84B | ||
| NTRA | NATERA INC | N/A | 32.51B | ||
| BIIB | BIOGEN INC | 10.53 | 25.87B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.5 | 22.16B | ||
| INCY | INCYTE CORP | 15.64 | 19.72B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.27B |
Related stock screener links
About LYEL
Company Profile
Lyell Immunopharma, Inc. operates as a holding company, which engages in the development of cell-based immunotherapies for human diseases. The company is headquartered in South San Francisco, California and currently employs 300 full-time employees. The company went IPO on 2021-06-17. The Company’s product candidates include LYL314 and LYL273. Its LYL314, which is in Phase I/II clinical development, is a dual-targeting CD19/CD20 CAR T-cell product candidate designed to increase complete response rates and prolong the duration of response as compared to the approved CD19-targeted CAR T-cell therapies and is under evaluation trial for the treatment of patients with relapsed and/or refractory large B-cell lymphoma. The firm has acquired the global rights to LYL273 (formerly GCC19CART), a novel autologous guanylyl cyclase-C (GCC)-targeted CAR T-cell product candidate for the treatment of metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.
Company Info
LYELL IMMUNOPHARMA INC
201 Haskins Way, Suite 301
South San Francisco CALIFORNIA US
CEO: Elizabeth Homans
Employees: 300
Phone: 16506950677
LYELL IMMUNOPHARMA INC / LYEL FAQ
What does LYELL IMMUNOPHARMA INC do?
Lyell Immunopharma, Inc. operates as a holding company, which engages in the development of cell-based immunotherapies for human diseases. The company is headquartered in South San Francisco, California and currently employs 300 full-time employees. The company went IPO on 2021-06-17. The Company’s product candidates include LYL314 and LYL273. Its LYL314, which is in Phase I/II clinical development, is a dual-targeting CD19/CD20 CAR T-cell product candidate designed to increase complete response rates and prolong the duration of response as compared to the approved CD19-targeted CAR T-cell therapies and is under evaluation trial for the treatment of patients with relapsed and/or refractory large B-cell lymphoma. The firm has acquired the global rights to LYL273 (formerly GCC19CART), a novel autologous guanylyl cyclase-C (GCC)-targeted CAR T-cell product candidate for the treatment of metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.
Can you provide the latest stock price for LYELL IMMUNOPHARMA INC?
The current stock price of LYEL is 38.6 USD. The price increased by 3.4% in the last trading session.
Does LYELL IMMUNOPHARMA INC pay dividends?
LYEL does not pay a dividend.
What is the ChartMill technical and fundamental rating of LYEL stock?
LYEL has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the growth outlook for LYELL IMMUNOPHARMA INC?
The Revenue of LYELL IMMUNOPHARMA INC (LYEL) is expected to grow by 2.27% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the next earnings date for LYEL stock?
LYELL IMMUNOPHARMA INC (LYEL) will report earnings on 2026-03-09, after the market close.
LYEL Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to LYEL. When comparing the yearly performance of all stocks, LYEL is one of the better performing stocks in the market, outperforming 99.13% of all stocks.
LYEL Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to LYEL. No worries on liquidiy or solvency for LYEL as it has an excellent financial health rating, but there are worries on the profitability.
LYEL Financial Highlights
Over the last trailing twelve months LYEL reported a non-GAAP Earnings per Share(EPS) of -12.56. The EPS increased by 20.51% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -79.83% | ||
| ROE | -98.95% | ||
| Debt/Equity | 0 |
LYEL Forecast & Estimates
For the next year, analysts expect an EPS growth of 28.6% and a revenue growth 2.27% for LYEL